Attached files
file | filename |
---|---|
EX-10.57 - MATERIAL CONTRACTS - PROTEONOMIX, INC. | ex1057.htm |
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 2, 2011
Commission File Number: 000-53750
PROTEONOMIX, INC.
(Name of Registrant in Its Charter)
Delaware (State or Other Jurisdiction of | 13-3842844 (I.R.S. Employer Identification No.) |
187 Mill Lane Mountainside, New Jersey (Address of Principal Executive Offices) |
07052 (Zip Code) |
(Issuers Telephone Number, Including Area Code) |
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
1
Section 1 Registrants Business and Operations
Item 1.01 Entry into a Material Definitive Agreement
On March 2, 2011, Proteonomix, Inc. (the Issuer) entered into an agreement with The Cohen McNiece Foundation, Inc. (the Foundation), a Florida not-for-profit corporation, to exclusively develop and license the Foundations UMK-121 Mobilization of Bone marrow Stem Cell technology (UMK-121) which is a proprietary technology based upon existing FDA approved drugs. The License imposes no upfront costs on the Issuer which will sublicense UMK-121 to its wholly owned subsidiary THOR BioPharma. The Issuer is required to make milestone payments to the Foundation upon 1) the issuance of a patent, 2) completion of Phase III trials and 3) commercialization which will require the payment of a 3% royalty on net sales.
Section 9 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.
Exhibit 10.57 Agreement Between Issuer and The Cohen McNiece Foundation, Inc. dated March 2, 2011
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PROTEONOMIX, INC.
Dated: March 8, 2011
By: /s/ Michael Cohen
Name: Michael Cohen
President
2